Clinical Trial Update: PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PD-1 with or without IL-4 inhibition in ER+ breast cancer is ongoing; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• IL-4 inhibition (interleukin-4 pathway inhibitor)
• PD-1

Snippet

Sponsor: Ottawa Hospital Research Institute | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN